0.4839
price up icon3.57%   0.0167
 
loading
Athira Pharma Inc stock is traded at $0.4839, with a volume of 603. It is up +3.57% in the last 24 hours and up +63.48% over the past month. Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
See More
Previous Close:
$0.4672
Open:
$0.4656
24h Volume:
603
Relative Volume:
0.00
Market Cap:
$18.89M
Revenue:
-
Net Income/Loss:
$-117.67M
P/E Ratio:
-0.1566
EPS:
-3.09
Net Cash Flow:
$-101.06M
1W Performance:
+25.98%
1M Performance:
+63.48%
6M Performance:
-12.80%
1Y Performance:
-85.64%
1-Day Range:
Value
$0.45
$0.4918
1-Week Range:
Value
$0.38
$0.4918
52-Week Range:
Value
$0.2195
$3.67

Athira Pharma Inc Stock (ATHA) Company Profile

Name
Name
Athira Pharma Inc
Name
Phone
(425) 620-8501
Name
Address
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Name
Employee
26
Name
Twitter
Name
Next Earnings Date
2024-12-07
Name
Latest SEC Filings
Name
ATHA's Discussions on Twitter

Compare ATHA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ATHA
Athira Pharma Inc
0.4839 15.47M 0 -117.67M -101.06M -3.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.10 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.53 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.56 29.19B 3.81B -644.79M -669.77M -6.24

Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-19-24 Downgrade Mizuho Outperform → Neutral
Sep-04-24 Downgrade BTIG Research Buy → Neutral
Sep-04-24 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Sep-04-24 Downgrade Rodman & Renshaw Buy → Neutral
Aug-19-24 Initiated Rodman & Renshaw Buy
Oct-17-22 Upgrade JMP Securities Mkt Perform → Mkt Outperform
Jul-07-22 Initiated Mizuho Buy
Jun-23-22 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-23-22 Downgrade Jefferies Buy → Hold
Jun-23-22 Downgrade Stifel Buy → Hold
May-10-22 Initiated BTIG Research Buy
Apr-21-22 Initiated Berenberg Buy
Dec-15-21 Initiated Goldman Neutral
Oct-13-20 Initiated Goldman Buy
Oct-13-20 Initiated JMP Securities Mkt Outperform
Oct-13-20 Initiated Jefferies Buy
Oct-13-20 Initiated Stifel Buy
View All

Athira Pharma Inc Stock (ATHA) Latest News

pulisher
03:37 AM

Athira Pharma (NASDAQ:ATHA) Trading Up 8.4% – Here’s Why - Defense World

03:37 AM
pulisher
12:45 PM

What analysts say about Athira Pharma Inc. stockFree Market Dynamics Reports - jammulinksnews.com

12:45 PM
pulisher
Jul 22, 2025

Is Athira Pharma Inc. a good long term investmentMarket-crushing stock picks - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

What drives Athira Pharma Inc. stock priceRecord-breaking capital gains - Autocar Professional

Jul 21, 2025
pulisher
Jul 17, 2025

Investors Can Still File Late Claims in Athira Pharma Settlement — Here’s How to Get Your Share - TradingView

Jul 17, 2025
pulisher
Jul 16, 2025

Lewy Body Dementia Market Set to Grow Substantially Through - openPR.com

Jul 16, 2025
pulisher
Jul 15, 2025

Why Athira Pharma Inc. stock attracts strong analyst attentionHigh Accuracy Alerts - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Athira Pharma Inc. stock performs during market volatilityDouble Profit With Half Risk - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Athira Pharma Inc. stock price move sharplyTop Gaining Low Risk Assets - Newser

Jul 15, 2025
pulisher
Jul 10, 2025

Athira Pharma (ATHA) Is Paying a $10M Settlement to Investors — Here’s How to Get Your Share - TradingView

Jul 10, 2025
pulisher
Jun 25, 2025

Is Athira Pharma, Inc. technically bullish or bearish? - MarketsMojo

Jun 25, 2025
pulisher
Jun 08, 2025

Two Sigma Advisers LP Has $149,000 Position in Athira Pharma, Inc. (NASDAQ:ATHA) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

ATHA LOSS ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Athira Pharma, Inc. Investors with LARGE LOSSES to Secure Counsel Before Important Deadline in Securities Class Action – ATHA - ACCESS Newswire

Jun 07, 2025
pulisher
Jun 05, 2025

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Jun 05, 2025
pulisher
Jun 05, 2025

Athira Pharma (NASDAQ:ATHA) Trading 9.2% Higher – Here’s Why - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

HAGENS BERMAN, NATIONAL ATTORNEYS, Alerts Athira Pharma (ATHA) Investors to Filing Of Securities Class Action, Advises Investors with Losses to Contact Firm's Attorneys Now - ACCESS Newswire

Jun 04, 2025
pulisher
Jun 03, 2025

Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference 2022 - Barchart.com

Jun 03, 2025
pulisher
Jun 02, 2025

Athira Pharma Holds Annual Stockholders Meeting - TipRanks

Jun 02, 2025
pulisher
Jun 01, 2025

Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Conference 2022 - Barchart.com

Jun 01, 2025
pulisher
May 27, 2025

This Athira Pharma Insider Increased Their Holding By 111% Last Year - Yahoo Finance

May 27, 2025
pulisher
May 20, 2025

Athira Pharma’s SWOT analysis: als drug developer’s stock faces pivotal phase - Investing.com

May 20, 2025
pulisher
May 15, 2025

Athira Pharma (ATHA) Highlights Promising Phase 1 Results for ALS Drug Candidate | ATHA Stock News - GuruFocus

May 15, 2025
pulisher
May 14, 2025

Athira Pharma to present data from first-in-human Phase 1 trial of ATH-1105 - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Athira Pharma (ATHA) Projected to Post Earnings on Wednesday - Defense World

May 14, 2025
pulisher
May 14, 2025

Athira Pharma Reports Reduced Losses and Strategic Focus - MSN

May 14, 2025
pulisher
May 13, 2025

Athira Pharma to Present Data from First-in-Human Phase 1 Clinic - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Athira Pharma to Present Data from First-in-Human Phase 1 - GlobeNewswire

May 13, 2025
pulisher
May 13, 2025

Breakthrough ALS Drug ATH-1105 Achieves Key Safety Milestones, Targets Patient Trials Late 2025 - Stock Titan

May 13, 2025
pulisher
May 10, 2025

Athira Pharma Reports First Quarter 2025 Financial Results and P - GuruFocus

May 10, 2025
pulisher
May 09, 2025

Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates - The Manila Times

May 09, 2025
pulisher
May 08, 2025

Athira Pharma, Inc. (NASDAQ:ATHA) Position Lowered by Renaissance Technologies LLC - Defense World

May 08, 2025
pulisher
May 07, 2025

Athira Pharma Slides As Insider Purchases Lose Another US$89k - simplywall.st

May 07, 2025
pulisher
May 06, 2025

Head-To-Head Review: NKGen Biotech (NYSE:NKGN) and Athira Pharma (NASDAQ:ATHA) - Defense World

May 06, 2025
pulisher
Apr 29, 2025

Phenylketonuria Clinical Trial Pipeline Appears Robust With - GlobeNewswire

Apr 29, 2025
pulisher
Apr 24, 2025

ATHAAthira Pharma, Inc. Latest Stock News & Market Updates - Stock Titan

Apr 24, 2025
pulisher
Apr 17, 2025

Athira Pharma shifts to Nasdaq Capital Market amid compliance bid By Investing.com - Investing.com India

Apr 17, 2025
pulisher
Apr 16, 2025

Athira Pharma shifts to Nasdaq Capital Market amid compliance bid - Investing.com Australia

Apr 16, 2025

Athira Pharma Inc Stock (ATHA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Athira Pharma Inc Stock (ATHA) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
CHURCH KEVIN
CHIEF SCIENTIFIC OFFICER
Jul 01 '25
Sale
0.29
8,526
2,502
168,901
Litton Mark James
President and CEO
Jun 30 '25
Option Exercise
0.00
108,334
0
350,925
Litton Mark James
President and CEO
Jul 01 '25
Sale
0.29
25,123
7,374
325,802
San Martin Javier
CHIEF MEDICAL OFFICER
Jun 30 '25
Option Exercise
0.00
46,666
0
82,507
San Martin Javier
CHIEF MEDICAL OFFICER
Jul 01 '25
Sale
0.29
10,842
3,182
71,665
Worthington Mark
General Counsel and CCO
Jun 30 '25
Option Exercise
0.00
36,666
0
120,401
Worthington Mark
General Counsel and CCO
Jul 01 '25
Sale
0.29
8,526
2,502
111,875
Renninger Robert
SVP, Finance and Accounting
Jun 30 '25
Option Exercise
0.00
12,359
0
112,083
Renninger Robert
SVP, Finance and Accounting
Jul 01 '25
Sale
0.29
2,897
850
109,186
$22.82
price up icon 4.66%
$35.94
price down icon 0.41%
$102.81
price down icon 0.07%
$27.66
price up icon 4.37%
$113.44
price up icon 1.82%
biotechnology ONC
$295.56
price down icon 0.03%
Cap:     |  Volume (24h):